According to the user, the reported stent separation has not occurred actually.Overgrowth and ingrowth of tumor occurred and the center of the stent was covered by the tumor.Therefore, the user mistook the growth of tumor for stent separation competitor's stent was placed on (b)(6) 2019.There have been no adverse effects to the patient reported.According to the sales rep, it is difficult to get further information for this complaint.
|
Us preclearance number # k163468.Device evaluation: the evo-22-27-9-d device of unknown lot number was not returned to cook ireland for evaluation.With the information provided, document based investigation was conducted.From complaint description: "according to the user, the reported stent separation has not occurred actually.Overgrowth and ingrowth of tumor occurred and the center of the stent was covered by the tumor.Therefore, the user mistook the growth of tumor for stent separation competitor's stent was placed." documents review including ifu review: as the evo-22-27-9-d device from unknown lot number, a review of the relevant manufacturing records cannot be conducted.Prior to distribution all evo-22-27-9-d devices are subject to visual inspection and functional checks to ensure device integrity.These inspections and functional checks are outlined in internal procedures in place at cirl.As per the instructions for use, (b)(4) which informs the user about the potential complications "additional complications include, but are not limited to: tumor ingrowth or overgrowth, stent occlusion." on review of the information provided, there is no evidence to suggest that the user did not follow the instructions for use.Root cause review: a definitive root cause could not be determined from the available information.A possible root cause could be attributed to patient condition related, as per instructions for use, tumor ingrowth or overgrowth are listed as a complication following the placement of this device.Summary: customer complaint is confirmed based on customer testimony.According to the initial reporter, competitor's stent was placed and there have been no adverse effects to the patient reported.Complaints of this nature will continue to be monitored for potential emerging trends.
|
According to the user, the reported stent separation has not occurred actually.Overgrowth and ingrowth of tumor occurred and the center of the stent was covered by the tumor.Therefore, the user mistook the growth of tumor for stent separation competitor's stent was placed on (b)(6) 2019.There have been no adverse effects to the patient reported.According to the sales rep, it is difficult to get further information for this complaint.
|